USA flag logo/image

An Official Website of the United States Government

Novel differentiation therapy for AML

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88934
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA134106
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INVENIO THERAPEUTICS, INC.
1100 CEDAR AVE, STE 285 CLEVELAND, OH 44106-3007
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Novel differentiation therapy for AML
Agency: HHS
Contract: 1R43CA134106-01
Award Amount: $128,230.00
 

Abstract:

DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adults and significantly lower in the elderly. The remarkab le success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia, with all trans-retinoic acid (ATRA) illustrates the great promise for agents with greater efficacy and less toxicity. Utilizing ATRA, the presumed cure of 75-85% of patients is possible. ATRA's remarkable success stems from the fact that AML is a disease characterized by the arrest of differentiation of immature myeloid cells. ATRA overcomes this block in differentiation by forcing leukemic cells to mature. After leu kemic cells undergo terminal differentiation, they lose their ability to proliferate. The aim of this phase I project is to demonstrate the promise of a novel nucleoside analogue with potent differentiation-inducing activity for the treatment of AML. This compound will be evaluated for differentiation activity using primary patient samples in both cell culture and bone marrow engraftment mouse xenograft experiments. In addition, this promising compound will be analyzed for potential toxicities, particularly myelotoxicity. As differentiation therapies are able to treat leukemia without the necessity for overt cytotoxicity, this work has the potential to lead to a more efficacious, less toxic, and better tolerated therapy for patients with AML. PUBLIC HEALTH R ELEVANCE: This project is highly relevant to public health as its main objective is to develop a novel therapy for patients with Acute Myeloid Leukemia that is both efficacious and has low toxicity. As the current AML therapeutics have low efficacy and hig h toxicities, there is a significant need for new therapies for AML.

Principal Investigator:

Small Business Information at Submission:

INVENIO THERAPEUTICS, INC.
INVENIO THERAPEUTICS, INC. 11000 Cedar Avenue, Suite 100 Cleveland, OH 44106

EIN/Tax ID: 156266652
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No